Computational Pathology Improves Risk Stratification of a Multi-gene Assay for Early Stage ER+ Breast Cancer
Overview
Authors
Affiliations
Prognostic markers currently utilized in clinical practice for estrogen receptor-positive (ER+) and lymph node-negative (LN-) invasive breast cancer (IBC) patients include the Nottingham grading system and Oncotype Dx (ODx). However, these biomarkers are not always optimal and remain subject to inter-/intra-observer variability and high cost. In this study, we evaluated the association between computationally derived image features from H&E images and disease-free survival (DFS) in ER+ and LN- IBC. H&E images from a total of n = 321 patients with ER+ and LN- IBC from three cohorts were employed for this study (Training set: D1 (n = 116), Validation sets: D2 (n = 121) and D3 (n = 84)). A total of 343 features relating to nuclear morphology, mitotic activity, and tubule formation were computationally extracted from each slide image. A Cox regression model (IbRiS) was trained to identify significant predictors of DFS and predict a high/low-risk category using D1 and was validated on independent testing sets D2 and D3 as well as within each ODx risk category. IbRiS was significantly prognostic of DFS with a hazard ratio (HR) of 2.33 (95% confidence interval (95% CI) = 1.02-5.32, p = 0.045) on D2 and a HR of 2.94 (95% CI = 1.18-7.35, p = 0.0208) on D3. In addition, IbRiS yielded significant risk stratification within high ODx risk categories (D1 + D2: HR = 10.35, 95% CI = 1.20-89.18, p = 0.0106; D1: p = 0.0238; D2: p = 0.0389), potentially providing more granular risk stratification than offered by ODx alone.
Multimodal histopathologic models stratify hormone receptor-positive early breast cancer.
Boehm K, El Nahhas O, Marra A, Waters M, Jee J, Braunstein L Nat Commun. 2025; 16(1):2106.
PMID: 40025017 PMC: 11873197. DOI: 10.1038/s41467-025-57283-x.
Hoang D, Dinstag G, Shulman E, Hermida L, Ben-Zvi D, Elis E Nat Cancer. 2024; 5(9):1305-1317.
PMID: 38961276 DOI: 10.1038/s43018-024-00793-2.
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence.
Dhungana A, Vannier A, Zhao F, Freeman J, Saha P, Sullivan M NPJ Breast Cancer. 2024; 10(1):46.
PMID: 38879577 PMC: 11180107. DOI: 10.1038/s41523-024-00651-5.
Boissin C, Wang Y, Sharma A, Weitz P, Karlsson E, Robertson S Breast Cancer Res. 2024; 26(1):90.
PMID: 38831336 PMC: 11145850. DOI: 10.1186/s13058-024-01840-7.
Regression-based Deep-Learning predicts molecular biomarkers from pathology slides.
El Nahhas O, Loeffler C, Carrero Z, van Treeck M, Kolbinger F, Hewitt K Nat Commun. 2024; 15(1):1253.
PMID: 38341402 PMC: 10858881. DOI: 10.1038/s41467-024-45589-1.